<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867607</url>
  </required_header>
  <id_info>
    <org_study_id>MRX6-201ver4-HMO-CTIL</org_study_id>
    <nct_id>NCT00867607</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis</brief_title>
  <official_title>A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Morria Biopharmaceuticals PLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of&#xD;
      Three Weeks of Daily Dermal Application of MRX-6 or steroid on the Treatment of Mild to&#xD;
      Moderate Allergic Contact Dermatitis of the Hand and Forearm.&#xD;
&#xD;
      Total number of patients: up to 80.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of three dose levels of topical MRX-6 (0.2%, 1.0% and 2% HyPE) when administered twice daily (b.i.d.) for 21 consecutive days</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in percentage change in each subject's total Physician's Visual Assessment (PVA) score from Baseline to Day 21 between the vehicle and MRX-6 treated hands/forearms.</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Allergic Contact Dermatitis</condition>
  <arm_group>
    <arm_group_label>MRX-6 (2%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MRX-6 (1%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MRX-6 (0.2%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRX-6</intervention_name>
    <description>b.i.d treatment for 21 days</description>
    <arm_group_label>MRX-6 (0.2%)</arm_group_label>
    <arm_group_label>MRX-6 (1%)</arm_group_label>
    <arm_group_label>MRX-6 (2%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid</intervention_name>
    <description>b.i.d. 21 days</description>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult men and women between 18 and 65 years old.&#xD;
&#xD;
          2. Male or non-pregnant female subjects who agree to comply with applicable contraceptive&#xD;
             requirements of the protocol. Details on potential child-bearing status, methods to&#xD;
             regularly exclude pregnancy throughout the study and acceptable forms of contraception&#xD;
             are provided in Section 3.4.1 of the protocol.&#xD;
&#xD;
          3. Satisfactory medical assessment with no clinically significant and relevant&#xD;
             abnormalities (of medical history, physical examination, clinical or laboratory&#xD;
             evaluation [hematology, biochemistry, urinalysis]) as determined by the Principal&#xD;
             Investigator, that might interfere with the assessment of the subjects dermatitis or&#xD;
             the assessment of the safety or efficacy of the Study Drug.&#xD;
&#xD;
          4. The subject must understand and be able, willing and likely to fully comply with study&#xD;
             procedures and restrictions.&#xD;
&#xD;
          5. Subject can understand and provide written informed consent to participate in the&#xD;
             study, in accordance with the International Conference on Harmonisation (ICH) Good&#xD;
             Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any&#xD;
             study-related procedures listed in Section 5.1.1 of the protocol.&#xD;
&#xD;
          6. Subject has mild to moderate bilateral allergic contact dermatitis on each hand,&#xD;
             possibly extending to the forearm, according to Physicians Visual Assessment as&#xD;
             described in Section 5.2.1 of the protocol. Mild to moderate disease is considered a&#xD;
             PVA score of 10 or greater and there should be no more than a 1-point difference&#xD;
             between hands.&#xD;
&#xD;
          7. Have a + reaction to the Standard European Series patch testing kit (Chemotechnique&#xD;
             Diagnostics Products, Malmo, Sweden) after application for 2 days, as described in&#xD;
             Section 5.2.2 of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or recurrent disease that could affect the action, absorption or disposition&#xD;
             of the Study Drug, or clinical or laboratory assessments.&#xD;
&#xD;
          2. Have used topical antihistamines in the past 2 weeks, topical corticosteroids or&#xD;
             received Psoralen plus ultra violet light therapy (PUVA) in the past 4 weeks, or have&#xD;
             taken oral retinoids, corticosteroids in the past 8 weeks (inhaled or intranasal&#xD;
             corticosteroids are allowed, if stable dose).&#xD;
&#xD;
          3. Use of any prescription or OTC medication (excluding hormonal contraceptive, hormonal&#xD;
             replacement therapy, inhaled or intranasal corticosteroids , or oral NSAIDs) that, in&#xD;
             the opinion of the Principal Investigator, could affect (improve or worsen) the&#xD;
             condition being studied, or could affect the action, absorption or disposition of the&#xD;
             Study Drug, or clinical or laboratory assessments.&#xD;
&#xD;
          4. Patients must not have used another investigational product or taken part in a&#xD;
             clinical trial within the last 30 days prior to enrolment.&#xD;
&#xD;
          5. Female patients who are pregnant or lactating, including females with a positive&#xD;
             pregnancy test at screening, must be excluded.&#xD;
&#xD;
          6. The subject known to have a positive hepatitis virus test (Hepatitis B virus surface&#xD;
             antigen or hepatitis C virus antibody) or a positive human immunodeficiency virus&#xD;
             (HIV) antibody test.&#xD;
&#xD;
          7. A history of hypersensitivity to any of the Study Drugs or their excipients.&#xD;
&#xD;
          8. Subject has any other significant dermatological condition that affects &gt;10% of the&#xD;
             body surface area or general medical condition that could interfere with the study&#xD;
             evaluation&#xD;
&#xD;
          9. Subject has any significant medical condition that could compromise immune&#xD;
             responsiveness&#xD;
&#xD;
         10. Subject has a history of alcoholism or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuval Ramot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah university hospital, Jerusalem Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Hadassah Hospital</name>
      <address>
        <city>Ein Karem, Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dermatology department, Hadassah university hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Ingber A, Cohen Y, Krimsky M, Yedgar S. A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.</citation>
    <PMID>17346444</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 22, 2009</study_first_submitted>
  <study_first_submitted_qc>March 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>April 19, 2015</last_update_submitted>
  <last_update_submitted_qc>April 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact dermatitis</keyword>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
    <mesh_term>Dermatitis, Allergic Contact</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

